# Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery

> **NCT01859182** · PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Adenocarcinoma of the Gallbladder
- Adenocarcinoma With Squamous Metaplasia of the Gallbladder
- Adult Primary Cholangiocellular Carcinoma
- Advanced Adult Primary Liver Cancer
- Cholangiocarcinoma of the Extrahepatic Bile Duct
- Localized Unresectable Adult Primary Liver Cancer
- Metastatic Extrahepatic Bile Duct Cancer
- Recurrent Adult Primary Liver Cancer
- Recurrent Extrahepatic Bile Duct Cancer
- Stage II Gallbladder Cancer
- Stage IIIA Gallbladder Cancer
- Stage IIIB Gallbladder Cancer
- Stage IVA Gallbladder Cancer
- Stage IVB Gallbladder Cancer
- Unresectable Extrahepatic Bile Duct Cancer

## Interventions

- **DRUG:** selumetinib
- **DRUG:** Akt inhibitor MK2206
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacogenomic studies
- **PROCEDURE:** quality-of-life assessment

## Key facts

- **NCT ID:** NCT01859182
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-01
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2014-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01859182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01859182, "Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01859182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*